Trump Administration's Rx Drug Price Disclosure Reg Seen As Unworkable

Lawyers say CMS proposed rule requiring TV ads to disclose drug's list price wouldn't survive First Amendment suit and competitors have no reason to try to enforce it.

First Amendment_1120355165_1200.jpg

The Centers for Medicare & Medicaid Services' proposed rule requiring TV ads for prescription drugs to disclose their list price has several significant fault lines, lawyers told the Pink Sheet, suggesting the reg may not hold up to challenges.

First and foremost is the question of whether the regulation violates the First Amendment by imposing an impermissible restriction on...

More from Pricing Debate

More from Market Access